Angiogenesis is a double-edged sword; it is a mechanism that defines the boundary
between health and disease. In spite of its central role in physiological homeostasis, it …

Excessive abnormal angiogenesis plays a pivotal role in tumor progression and is a
hallmark of solid tumors. This process is driven by an imbalance between pro-and anti …

Pharmacological inhibition of VEGF-A has proven to be effective in inhibiting angiogenesis
and vascular leak associated with cancers and various eye diseases. However, little …

The dependency of the growth of tumors on blood vessels, once considered a doubtful
proposition, has become a major avenue of research and drug development. This review …

The regulation of vascular endothelial growth factor A (VEGF) is critical to
neovascularization in numerous tissues under physiological and pathological conditions …

Age-related macular degeneration (AMD) is the leading cause of visual impairment in the
aging population with a limited understanding of its pathogenesis and the number of …

Less than 5 years ago, it was still not clear whether anti-angiogenic drugs would prove
successful in the clinic. After numerous patients with cancer or age-related macular …

Bevacizumab is the first antiangiogenic therapy proven to slow metastatic disease
progression in patients with cancer. Although it has changed clinical practice, some patients …

Angiogenesis, a process of new blood vessel formation, is a prerequisite for tumour growth
to supply the proliferating tumour with oxygen and nutrients. The angiogenic process may …

Purpose The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in
combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved …